Resmed Inc’s filing revealed that its Chief Executive Officer Farrell Michael J. unloaded Company’s shares for reported $2.01 million on Jun 09 ’25. In the deal valued at $251.21 per share,8,009 shares were sold. As a result of this transaction, Farrell Michael J. now holds 455,503 shares worth roughly $114.64 million.
Then, Farrell Michael J. bought 8,009 shares, generating $2,018,268 in total proceeds.
Before that, FARRELL PETER C sold 2,000 shares. Resmed Inc shares valued at $494,640 were divested by the Director at a price of $247.32 per share. As a result of the transaction, FARRELL PETER C now holds 69,218 shares, worth roughly $17.42 million.
Morgan Stanley initiated its Resmed Inc [RMD] rating to an Overweight in a research note published on March 19, 2025; the price target was $280. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Goldman began covering RMD with “Buy” recommendation on January 16, 2025. Piper Sandler started covering the stock on January 10, 2025. It rated RMD as “a Neutral”.
Price Performance Review of RMD
On Monday, Resmed Inc [NYSE:RMD] saw its stock jump 0.94% to $251.68. Over the last five days, the stock has gained 0.28%. Resmed Inc shares have risen nearly 10.05% since the year began. Nevertheless, the stocks have risen 19.34% over the past one year. While a 52-week high of $263.05 was reached on 01/30/25, a 52-week low of $179.42 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 249.52, which if violated will result in even more drops to 247.35. On the upside, there is a resistance level at 253.94. A further resistance level may holdings at 256.19.
The most recent change occurred on December 13, 2024 when Stifel began covering the stock and recommended ‘”a Hold”‘ rating along with a $250 price target.
